We respond to research about breast cancer surgery margins
22 Sept 2022
We respond to research about physical activity and breast cancer risk
07 Sept 2022
Breast Cancer Now responds to the HSJ and BBC Newsnight's joint special investigation about long cancer waits
11 Aug 2022
We respond to MP Dawn Butler's mission to find the Million Missing Mammograms
Following MP Dawn Butler's appearance on This Morning today, announcing her mission to find the Million Missing Mammograms, Breast Cancer Now said:
02 Aug 2022
Breast Cancer Now welcomes NICE decision to recommend alpelisib with fulvestrant for routine use on the NHS
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
14 Jul 2022
Breast Cancer Now celebrates landmark victory as Trodelvy is recommended for use on the NHS in England
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
14 Jul 2022
We respond to the approval of breast cancer drug abemaciclib for routine use on the NHS
In response to the news abemaciclib has been approved by THE National Institute for Health and Care Excellence (NICE) for routine use on the NHS with hormone therapy, following surgery for certain women with hormone receptor positive, HER2 negative primary breast cancer, whose disease is lymph node positive, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
17 Jun 2022
We respond to research that suggests drugs that neutralise progesterone activity could be a potential risk-reducing treatment for women with altered BRCA genes
In response to research published in Genome Medicine, and part-funded by Breast Cancer Now, which suggests drugs that neutralise progesterone activity could be a potential risk-reducing treatment for women with altered BRCA genes, Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
15 Jun 2022
We respond to the Royal College of Radiologists’ clinical radiology and clinical oncology census reports for 2021
In response to today’s Royal College of Radiologists’ clinical radiology and clinical oncology censuses, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
10 Jun 2022
We respond to new findings from the Lumina trial which suggest some patients could avoid radiotherapy
Breast Cancer Now has commented on findings from the Lumina trial presented at the American Society of Clinical Oncology (ASCO).
07 Jun 2022
We comment on new research which shows the drug trastuzumab deruxtecan may benefit even more breast cancer patients
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
05 Jun 2022
We welcome NICE approval of pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) for routine use on the NHS
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
25 May 2022